What kind of drug does imatinib belong to?

Imatinib is a targeted therapy, specifically a class of tyrosine kinase inhibitors. It is primarily used to treat chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST), as well as other cancers caused by specific genetic mutations. Imatinib blocks the proliferation and growth of cancer cells by specifically targeting and inhibiting abnormal tyrosine kinases in cancer cells. The drug targets the product of the BCR-ABL fusion gene, BCR-ABL tyrosine kinase, an enzyme that has abnormal activity in most patients with chronic myelogenous leukemia.

Imatinib’s mechanism of action is different from traditional chemotherapy drugs. Traditional chemotherapy usually kills cancer cells by interfering with all rapidly dividing cells, but this can also damage normal cells, causing serious side effects. Imatinib, on the other hand, minimizes the impact on normal cells by selectively inhibiting specific targets in cancer cells, thus reducing adverse reactions. This precise targeted treatment strategy allows imatinib to demonstrate better efficacy and tolerability in many patients.

Since its first approval in the United States in 2001, imatinib has quickly become a standard drug for the treatment of chronic myelogenous leukemia, and has also shown significant efficacy in the treatment of other diseases such as gastrointestinal stromal tumors. Its invention marks the arrival of the era of targeted therapy and brings hope of survival to many cancer patients. Especially in those diseases that cannot be effectively controlled through traditional treatment methods, the application of imatinib is extremely revolutionary.

In general, imatinib is a tyrosine kinase inhibitor among targeted therapy drugs. Because of its precise targeting effect and relatively low side effects, it has become an important drug for the treatment of specific cancers. Globally, it has helped countless patients live longer and significantly improve their quality of life.